You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,236,292


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,236,292
Title:Liquid depot formulations
Abstract:The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
Inventor(s):Thuresson Krister, Tiberg Fredrik, Johansson Markus, Harwigsson Ian, Joabsson Fredrik, Johnsson Markus
Assignee:Camurus AB
Application Number:US11628007
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 8,236,292

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-001 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-002 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-003 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-004 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-005 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-006 May 23, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
Braeburn BRIXADI buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 210136-007 May 23, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,236,292

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E401054 ⤷  Sign Up
Austria E462409 ⤷  Sign Up
Austria E501710 ⤷  Sign Up
Australia 2005249274 ⤷  Sign Up
Australia 2005324794 ⤷  Sign Up
Australia 2010202794 ⤷  Sign Up
Australia 2013294915 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.